The historical data trend for Turnstone Biologics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Turnstone Biologics's EV-to-EBIT
For the Biotechnology subindustry, Turnstone Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turnstone Biologics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Turnstone Biologics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Turnstone Biologics's EV-to-EBIT falls into.
Turnstone Biologics's current Enterprise Value is $-13.61 Mil.
Turnstone Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Turnstone Biologics's Enterprise Value for the quarter that ended in Mar. 2024 was $-14.53 Mil.
Turnstone Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turnstone Biologics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Turnstone Biologics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Turnstone Biologics (Turnstone Biologics) Business Description
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSBX has been successfully added to your 